Compositions and uses of alpha-adrenergic agents
The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.
1. A method for increasing the vertical separation of the upper and lower eyelids of an eye of a subject, comprising
administering to the exterior surface of the upper eyelid of the subject a gel composition comprising an effective amount of oxymetazoline or a salt thereof and a permeation enhancer,
wherein the effective amount of oxymetazoline or a salt thereof is from about 0.5 mg to 8 mg per dose, and
wherein the increasing the vertical separation of the upper and lower eyelids comprises retraction of the upper eyelids by about 0.5 mm or more.
2. The method of claim 1 , wherein the increasing the vertical separation of the upper and lower eyelids comprises retracting the upper eyelid by about 1 mm or more.
3. The method of claim 1 , wherein the gel composition comprises from about 3 to 6 mg of oxymetazoline or a salt thereof per dose.
4. The method of claim 1 , wherein the permeation enhancer is less than 40% by weight of the gel composition.
5. The method of claim 1 , wherein the permeation enhancer is less than 20% by weight of the gel composition.
6. The method of claim 1 , wherein the permeation enhancer is selected from ethanol, propylene glycol, dodecyl-N,N-dimethyl-aminoacetate, ethylacetate, azone, sodium dodecyl sulfate, d-limonene, oleic acid, 1,3-diphenyl-urea, N-methyl-2-pyrrolidone, beta-cyclodextrin, and dimethylsulfoxide.
7. The method of claim 1 , wherein the permeation enhancer comprises an alcohol.
8. The method of claim 7 , wherein the permeation enhancer comprises propylene glycol.
9. The method of claim 1 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 2-fold or greater relative to a composition without the permeation enhancer.
10. The method of claim 9 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 3-fold or greater relative to a composition without the permeation enhancer.
11. The method of claim 1 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 0.5 mm or more relative to a composition without the permeation enhancer.
12. The method of claim 1 , wherein oxymetazoline or a salt thereof permeates through the stratum corneum and septal fat pad to contact Müller's muscle.
13. The method of claim 1 , wherein the administering comprises administering the gel composition at most 3 times per day.
14. The method of claim 1 , wherein the gel composition is a controlled-release composition.
15. The method of claim 1 , wherein the gel composition further comprises one or more dermatologically acceptable carriers.
16. The method of claim 1 , wherein the one or more dermatologically acceptable carriers are individually selected from buffers, preservatives, gelling agents, rheological modifiers and stabilizers, moisturizers, and humectants.
17. The method of claim 1 , further comprising one or more cosmetic excipients.
18. The method of claim 17 , wherein the one or more cosmetic excipients are individually selected from sunscreens, fragrances, pigments and antioxidants.
19. The method of claim 1 , wherein retraction of the upper eyelids by about 0.5 mm or more comprises an increase in the vertical separation of the upper and lower eyelids relative to the position of the eyelids prior to administration of oxymetazoline or a salt.